The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Immunity of patients with multiple myeloma after vaccination against COVID-19
Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, reports the results of a study that used a comprehensive immune phenotyping framework to assess the immune responses of patients with multiple myeloma to SARS-CoV-2 vaccination. Multiple myeloma is associated with humoral and cellular immunosuppression, making patients more susceptible to severe COVID-19 infection. Analysis of the adaptive and innate immune cell compartments of patients with multiple myeloma revealed that specific cytokine-responsive NK cell and T cell populations appeared overrepresented in patients with successful vaccination responses, as well as a similar overrepresentation of these immune cells after breakthrough infections. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Honoraria; Phialogics: Honoraria.
